Lovenox (enoxaparin sodium) is an antithrombolytic agent also known as low molecular weight heparin (LMWH). Lovenox is FDA approved for use in the prevention of deep vein thrombosis (DVT) after hip, knee, and abdominal surgery. It also has been approved for use with unstable angina and non-Q wave myocardial infarction (MI). Lovenox produces a predictable antithrombolytic response so that serial partial thromboplastin times (PTT) are no longer necessary over a normal course of treatment. However, periodic tests such as complete blood counts (CBC) and stool occult blood tests are recommended during treatment. Caution should be used with patients who have a sensitivity to heparin, pork products, or with active bleeding. Overdose treatment is identical to heparin, using protamine sulfate. For more information on Lovenox check the following sites:

Treatment of DVT

Treatment after Abdominal Surgery

Treatment for Unstable Angina and non-Q wave MI

Company Product Information


Drug Facts and Comparisons. January 2000 pg 163-165b.

Last updated:  October 25, 2000


NP Central
10024 S.E. 240th St., Suite #102, Kent, WA 98031
Phone: 253.852.9042 Fax: 253.852.7725
NP Central Gateway

Use of this section indicates you agree to the Terms of Use.
Copyright 1994-2003 NP Central